Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D83YSR
|
|||
| Drug Name |
680C91
|
|||
| Synonyms |
163239-22-3; CHEMBL355606; 6-Fluoro-3-((E)-2-pyridin-3-yl-vinyl)-1H-indole; 6-fluoro-3-[(E)-2-pyridin-3-ylethenyl]-1H-indole; SCHEMBL3262721; SCHEMBL3262726; ZINC19965; CHEBI:131851; EX-A4573; BDBM50289137; s8997; AKOS024458137; 680C91, >=98% (HPLC); 680C-91; (e)-6-fluoro-3-[2-(3-pyridyl)vinyl]-1h-indole; (E)-6-Fluoro-3-(2-(pyridin-3-yl)vinyl)-1H-indole; 6-fluoro-3-[(E)-2-(pyridin-3-yl)vinyl]-1H-indole; Q27225279; 6-Fluoro-3-[(1E)-2-(3-pyridinyl)ethenyl]-1H-indole; 1H-Indole, 6-fluoro-3-[(1E)-2-(3-pyridinyl)ethenyl]-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Preclinical | [1] | |
| Company |
Glaxo Wellcome
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H11FN2
|
|||
| Canonical SMILES |
C1=CC(=CN=C1)C=CC2=CNC3=C2C=CC(=C3)F
|
|||
| InChI |
1S/C15H11FN2/c16-13-5-6-14-12(10-18-15(14)8-13)4-3-11-2-1-7-17-9-11/h1-10,18H/b4-3+
|
|||
| InChIKey |
YBSDQTBCNYWBMX-ONEGZZNKSA-N
|
|||
| CAS Number |
CAS 163239-22-3
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:131851
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tryptophan 2,3-dioxygenase (TDO) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Tryptophan metabolism | |||
| Metabolic pathways | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401. | |||
| REF 2 | Effects of IDO1 and TDO2 inhibition on cognitive deficits and anxiety following LPS-induced neuroinflammation. Acta Neuropsychiatr. 2020 Feb;32(1):43-53. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.